Recombinant human erythropoietin usage in a large academic medical center

American Journal of Managed Care

Volumn 8, Issue 8, 2002, Pages 742-747

  Bilenker, Joshua H ^a   Demers, Richard ^a   Porter, David L ^a   Wasserstein, Alan G ^a   Peters, Erika ^a   Manaker, Scott ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER; CHRONIC KIDNEY FAILURE; COMPUTER PROGRAM; COST MINIMIZATION ANALYSIS; DATA BASE; DRUG ACTIVITY; DRUG COST; DRUG INDICATION; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; ERYTHROCYTE TRANSFUSION; GENERAL PRACTICE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEMATOLOGY; HOSPITAL DEPARTMENT; HOSPITAL PATIENT; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; ONCOLOGY; ORTHOPEDIC SURGERY; PHARMACODYNAMICS; PHYSICIAN; PRIORITY JOURNAL; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANEMIA; DRUG COSTS; DRUG UTILIZATION REVIEW; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LENGTH OF STAY; PHARMACY SERVICE, HOSPITAL; PHILADELPHIA; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 0036690866     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
2. Epogen product information
3. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a Phase III multicenter clinical trial
4. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
5. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
6. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
7. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice
8. Recombinant human erythropoietin for patients with AIDS treated with zidovudine
9. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: Overview of four clinical trials
10. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation
11. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement
12. A safety and efficacy comparison study of two dosing regimens of Epoetin alfa in patients undergoing major orthopedic surgery
13. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
14. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease
15. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial
16. Erythropoietin response is blunted in critically ill patients
17. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
18. A controlled trial of recombinant human erythropoietin after bone marrow transplantation
19. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: Results of a prospective controlled randomized trial
20. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: Results of a randomized, double-blind study with high-dose erythropoietin
21. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants
22. A randomized trial of recombinant human erythropoietin (rHuEPO) after purged autologous bone marrow transplant (BMT)
23. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center
24. Lessons from an epidemic, again
25. Controversies in selection of epoetin dosages: Issues and answers
26. Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration
27. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
28. Chemotherapy-induced anemia in adults: Incidence and treatment
29. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants
30. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study
31. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants
32. Erythropoietin: Not yet a standard treatment for anemia of prematurity
33. Neocytolysis contributes to the anemia of renal disease
34. Neocytolysis on descent from altitude: A newly recognized mechanism for the control of red cell mass
35. Out of thin air: The evolving enigma of erythropoietin and neocytolysis